Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

An optimised tissue disaggregation and data processing pipeline for characterising fibroblast phenotypes using single-cell RNA sequencing.

Waise S, Parker R, Rose-Zerilli MJJ, Layfield DM, Wood O, West J, Ottensmeier CH, Thomas GJ, Hanley CJ.

Sci Rep. 2019 Jul 3;9(1):9580. doi: 10.1038/s41598-019-45842-4.

2.

Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer.

Clarke J, Panwar B, Madrigal A, Singh D, Gujar R, Wood O, Chee SJ, Eschweiler S, King EV, Awad AS, Hanley CJ, McCann KJ, Bhattacharyya S, Woo E, Alzetani A, Seumois G, Thomas GJ, Ganesan AP, Friedmann PS, Sanchez-Elsner T, Ay F, Ottensmeier CH, Vijayanand P.

J Exp Med. 2019 Jun 21. pii: jem.20190249. doi: 10.1084/jem.20190249. [Epub ahead of print]

PMID:
31227543
3.

Withdrawal: Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma.

Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A.

Mol Cell Proteomics. 2019 Jun;18(6):1270. doi: 10.1074/mcp.W119.001571. No abstract available.

4.

Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.

Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A.

Mol Cell Proteomics. 2019 Jun;18(6):1255-1268. doi: 10.1074/mcp.RA119.001524.

PMID:
31154438
5.

HPV Epitope Processing Differences Correlate with ERAP1 Allotype and Extent of CD8+ T-cell Tumor Infiltration in OPSCC.

Reeves E, Wood O, Ottensmeier CH, King EV, Thomas GJ, Elliott T, James E.

Cancer Immunol Res. 2019 Jul;7(7):1202-1213. doi: 10.1158/2326-6066.CIR-18-0498. Epub 2019 May 31.

PMID:
31151965
6.

Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer.

Hardy-Werbin M, Rocha P, Arpi O, Taus Á, Nonell L, Durán X, Villanueva X, Joseph-Pietras D, Nolan L, Danson S, Griffiths R, Lopez-Botet M, Rovira A, Albanell J, Ottensmeier C, Arriola E.

Oncoimmunology. 2019 Mar 27;8(6):e1593810. doi: 10.1080/2162402X.2019.1593810. eCollection 2019.

PMID:
31069160
7.

Recent advances in the molecular landscape of lung neuroendocrine tumors.

Pelosi G, Bianchi F, Hofman P, Pattini L, Ströbel P, Calabrese F, Naheed S, Holden C, Cave J, Bohnenberger H, Dinter H, Harari S, Albini A, Sonzogni A, Papotti M, Volante M, Ottensmeier CH.

Expert Rev Mol Diagn. 2019 Apr;19(4):281-297. doi: 10.1080/14737159.2019.1595593. Epub 2019 Mar 27.

PMID:
30900485
8.

Importance of the immune system in head and neck cancer.

Mirza AH, Thomas G, Ottensmeier CH, King EV.

Head Neck. 2019 Aug;41(8):2789-2800. doi: 10.1002/hed.25716. Epub 2019 Feb 28. Review.

PMID:
30821023
9.

Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma.

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Straten PT, Martinez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piro J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Lower M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Bruck A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rossler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W.

Nature. 2019 Feb;566(7745):E13. doi: 10.1038/s41586-019-0959-z.

PMID:
30733620
10.

Recurrent group A Streptococcus tonsillitis is an immunosusceptibility disease involving antibody deficiency and aberrant TFH cells.

Dan JM, Havenar-Daughton C, Kendric K, Al-Kolla R, Kaushik K, Rosales SL, Anderson EL, LaRock CN, Vijayanand P, Seumois G, Layfield D, Cutress RI, Ottensmeier CH, Lindestam Arlehamn CS, Sette A, Nizet V, Bothwell M, Brigger M, Crotty S.

Sci Transl Med. 2019 Feb 6;11(478). pii: eaau3776. doi: 10.1126/scitranslmed.aau3776.

11.

HPV, tumour metabolism and novel target identification in head and neck squamous cell carcinoma.

Fleming JC, Woo J, Moutasim K, Mellone M, Frampton SJ, Mead A, Ahmed W, Wood O, Robinson H, Ward M, Woelk CH, Ottensmeier CH, King E, Kim D, Blaydes JP, Thomas GJ.

Br J Cancer. 2019 Feb;120(3):356-367. doi: 10.1038/s41416-018-0364-7. Epub 2019 Jan 17.

12.

Actively personalized vaccination trial for newly diagnosed glioblastoma.

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Thor Straten P, Martínez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piró J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Löwer M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Brück A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rössler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W.

Nature. 2019 Jan;565(7738):240-245. doi: 10.1038/s41586-018-0810-y. Epub 2018 Dec 19. Erratum in: Nature. 2019 Feb;566(7745):E13.

PMID:
30568303
13.

Implications of Tuberculosis Reactivation after Immune Checkpoint Inhibition.

Elkington PT, Bateman AC, Thomas GJ, Ottensmeier CH.

Am J Respir Crit Care Med. 2018 Dec 1;198(11):1451-1453. doi: 10.1164/rccm.201807-1250LE. No abstract available.

14.

Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma.

Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich PY, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee HG, Sahin U, Singh H, Admon A.

Mol Cell Proteomics. 2018 Nov;17(11):2132-2145. doi: 10.1074/mcp.RA118.000792. Epub 2018 Aug 2. Retraction in: Mol Cell Proteomics. 2019 Jun;18(6):1270.

PMID:
30072578
15.

Paracrine signalling during ZEB1-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in lung fibrosis.

Yao L, Conforti F, Hill C, Bell J, Drawater L, Li J, Liu D, Xiong H, Alzetani A, Chee SJ, Marshall BG, Fletcher SV, Hancock D, Coldwell M, Yuan X, Ottensmeier CH, Downward J, Collins JE, Ewing RM, Richeldi L, Skipp P, Jones MG, Davies DE, Wang Y.

Cell Death Differ. 2019 May;26(5):943-957. doi: 10.1038/s41418-018-0175-7. Epub 2018 Jul 26.

16.

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.

Corrie PG, Marshall A, Nathan PD, Lorigan P, Gore M, Tahir S, Faust G, Kelly CG, Marples M, Danson SJ, Marshall E, Houston SJ, Board RE, Waterston AM, Nobes JP, Harries M, Kumar S, Goodman A, Dalgleish A, Martin-Clavijo A, Westwell S, Casasola R, Chao D, Maraveyas A, Patel PM, Ottensmeier CH, Farrugia D, Humphreys A, Eccles B, Young G, Barker EO, Harman C, Weiss M, Myers KA, Chhabra A, Rodwell SH, Dunn JA, Middleton MR; AVAST-M Investigators .

Ann Oncol. 2018 Aug 1;29(8):1843-1852. doi: 10.1093/annonc/mdy229.

17.

Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice.

Califano R, Lal R, Lewanski C, Nicolson MC, Ottensmeier CH, Popat S, Hodgson M, Postmus PE.

Future Oncol. 2018 Oct;14(23):2415-2431. doi: 10.2217/fon-2018-0330. Epub 2018 Jul 6.

18.

Nanoscale dysregulation of collagen structure-function disrupts mechano-homeostasis and mediates pulmonary fibrosis.

Jones MG, Andriotis OG, Roberts JJ, Lunn K, Tear VJ, Cao L, Ask K, Smart DE, Bonfanti A, Johnson P, Alzetani A, Conforti F, Doherty R, Lai CY, Johnson B, Bourdakos KN, Fletcher SV, Marshall BG, Jogai S, Brereton CJ, Chee SJ, Ottensmeier CH, Sime P, Gauldie J, Kolb M, Mahajan S, Fabre A, Bhaskar A, Jarolimek W, Richeldi L, O'Reilly KM, Monk PD, Thurner PJ, Davies DE.

Elife. 2018 Jul 3;7. pii: e36354. doi: 10.7554/eLife.36354.

19.

Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial.

Patel PM, Ottensmeier CH, Mulatero C, Lorigan P, Plummer R, Pandha H, Elsheikh S, Hadjimichael E, Villasanti N, Adams SE, Cunnell M, Metheringham RL, Brentville VA, Machado L, Daniels I, Gijon M, Hannaman D, Durrant LG.

Oncoimmunology. 2018 Feb 22;7(6):e1433516. doi: 10.1080/2162402X.2018.1433516. eCollection 2018.

20.

CD103+CD8+ Lymphocytes Characterize the Immune Infiltration in a Case With Pseudoprogression in Squamous NSCLC.

Rocha P, Hardy-Werbin M, Naranjo D, Taus Á, Rodrigo M, Zuccarino F, Roth R, Wood O, Ottensmeier CH, Arriola E.

J Thorac Oncol. 2018 Oct;13(10):e193-e196. doi: 10.1016/j.jtho.2018.05.008. Epub 2018 Jul 19. No abstract available.

PMID:
29775806
21.

CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial.

Fennell DA, Kirkpatrick E, Cozens K, Nye M, Lester J, Hanna G, Steele N, Szlosarek P, Danson S, Lord J, Ottensmeier C, Barnes D, Hill S, Kalevras M, Maishman T, Griffiths G.

Trials. 2018 Apr 18;19(1):233. doi: 10.1186/s13063-018-2602-y.

22.

Linear doggybone DNA vaccine induces similar immunological responses to conventional plasmid DNA independently of immune recognition by TLR9 in a pre-clinical model.

Allen A, Wang C, Caproni LJ, Sugiyarto G, Harden E, Douglas LR, Duriez PJ, Karbowniczek K, Extance J, Rothwell PJ, Orefo I, Tite JP, Stevenson FK, Ottensmeier CH, Savelyeva N.

Cancer Immunol Immunother. 2018 Apr;67(4):627-638. doi: 10.1007/s00262-017-2111-y. Epub 2018 Jan 12.

23.

Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab.

Hardy-Werbin M, Arpí O, Taus A, Rocha P, Joseph-Pietras D, Nolan L, Danson S, Griffiths R, Lopez-Botet M, Rovira A, Albanell J, Ottensmeier CH, Arriola E.

Oncoimmunology. 2017 Nov 27;7(2):e1395125. doi: 10.1080/2162402X.2017.1395125. eCollection 2018.

24.

Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease.

Karydis I, Gangi A, Wheater MJ, Choi J, Wilson I, Thomas K, Pearce N, Takhar A, Gupta S, Hardman D, Sileno S, Stedman B, Zager JS, Ottensmeier C.

J Surg Oncol. 2018 May;117(6):1170-1178. doi: 10.1002/jso.24956. Epub 2017 Dec 28.

25.

COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss.

Crabb SJ, Martin K, Abab J, Ratcliffe I, Thornton R, Lineton B, Ellis M, Moody R, Stanton L, Galanopoulou A, Maishman T, Geldart T, Bayne M, Davies J, Lamb C, Popat S, Joffe JK, Nutting C, Chester J, Hartley A, Thomas G, Ottensmeier C, Huddart R, King E.

Eur J Cancer. 2017 Dec;87:75-83. doi: 10.1016/j.ejca.2017.09.033. Epub 2017 Nov 10.

26.

Towards personalised medicine in lung and thymus neuroendocrine tumours.

Pelosi G, Cave J, Ottensmeier CH.

Lancet Oncol. 2017 Dec;18(12):1563-1565. doi: 10.1016/S1470-2045(17)30784-2. Epub 2017 Oct 23. No abstract available.

PMID:
29074101
27.

Head and Neck Squamous Cell Carcinomas Are Characterized by a Stable Immune Signature Within the Primary Tumor Over Time and Space.

Wood O, Clarke J, Woo J, Mirza AH, Woelk CH, Thomas GJ, Vijayanand P, King E, Ottensmeier CH.

Clin Cancer Res. 2017 Dec 15;23(24):7641-7649. doi: 10.1158/1078-0432.CCR-17-0373. Epub 2017 Sep 26.

28.

Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4.

Hanley CJ, Mellone M, Ford K, Thirdborough SM, Mellows T, Frampton SJ, Smith DM, Harden E, Szyndralewiez C, Bullock M, Noble F, Moutasim KA, King EV, Vijayanand P, Mirnezami AH, Underwood TJ, Ottensmeier CH, Thomas GJ.

J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx121.

29.

Evaluating the effect of immune cells on the outcome of patients with mesothelioma.

Chee SJ, Lopez M, Mellows T, Gankande S, Moutasim KA, Harris S, Clarke J, Vijayanand P, Thomas GJ, Ottensmeier CH.

Br J Cancer. 2017 Oct 24;117(9):1341-1348. doi: 10.1038/bjc.2017.269. Epub 2017 Aug 17.

30.

Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer.

Ganesan AP, Clarke J, Wood O, Garrido-Martin EM, Chee SJ, Mellows T, Samaniego-Castruita D, Singh D, Seumois G, Alzetani A, Woo E, Friedmann PS, King EV, Thomas GJ, Sanchez-Elsner T, Vijayanand P, Ottensmeier CH.

Nat Immunol. 2017 Aug;18(8):940-950. doi: 10.1038/ni.3775. Epub 2017 Jun 19.

31.

Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR).

Seckl MJ, Ottensmeier CH, Cullen M, Schmid P, Ngai Y, Muthukumar D, Thompson J, Harden S, Middleton G, Fife KM, Crosse B, Taylor P, Nash S, Hackshaw A.

J Clin Oncol. 2017 May 10;35(14):1506-1514. doi: 10.1200/JCO.2016.69.7391. Epub 2017 Feb 27.

32.

Induction of fibroblast senescence generates a non-fibrogenic myofibroblast phenotype that differentially impacts on cancer prognosis.

Mellone M, Hanley CJ, Thirdborough S, Mellows T, Garcia E, Woo J, Tod J, Frampton S, Jenei V, Moutasim KA, Kabir TD, Brennan PA, Venturi G, Ford K, Herranz N, Lim KP, Clarke J, Lambert DW, Prime SS, Underwood TJ, Vijayanand P, Eliceiri KW, Woelk C, King EV, Gil J, Ottensmeier CH, Thomas GJ.

Aging (Albany NY). 2016 Dec 15;9(1):114-132. doi: 10.18632/aging.101127.

33.

Human Papillomavirus Drives Tumor Development Throughout the Head and Neck: Improved Prognosis Is Associated With an Immune Response Largely Restricted to the Oropharynx.

Chakravarthy A, Henderson S, Thirdborough SM, Ottensmeier CH, Su X, Lechner M, Feber A, Thomas GJ, Fenton TR.

J Clin Oncol. 2016 Dec;34(34):4132-4141. Epub 2016 Oct 31.

34.

BILATERAL METASTATIC CUTANEOUS MELANOMA TO RETINA AND VITREOUS AFTER IPILIMUMAB TREATED WITH PARS PLANA VITRECTOMY AND RADIOTHERAPY.

Kanavati S, Ottensmeier C, Foria V, Krishnan R.

Retin Cases Brief Rep. 2018 Summer;12(3):184-187. doi: 10.1097/ICB.0000000000000477.

PMID:
27828902
35.

Evaluation of immune infiltration in the colonic mucosa of patients with ipilimumab-related colitis.

Arriola E, Wheater M, Lopez MA, Thomas G, Ottensmeier C.

Oncoimmunology. 2016 Jul 15;5(9):e1209615. eCollection 2016.

36.

Linked CD4 T Cell Help: Broadening Immune Attack Against Cancer by Vaccination.

Savelyeva N, Allen A, Chotprakaikiat W, Harden E, Jobsri J, Godeseth R, Wang Y, Stevenson F, Ottensmeier C.

Curr Top Microbiol Immunol. 2017;405:123-143. doi: 10.1007/82_2016_500. Review.

PMID:
27704269
37.

A plant-expressed conjugate vaccine breaks CD4(+) tolerance and induces potent immunity against metastatic Her2(+) breast cancer.

Chotprakaikiat W, Allen A, Bui-Minh D, Harden E, Jobsri J, Cavallo F, Gleba Y, Stevenson FK, Ottensmeier C, Klimyuk V, Savelyeva N.

Oncoimmunology. 2016 Apr 22;5(6):e1166323. doi: 10.1080/2162402X.2016.1166323. eCollection 2016 Jun.

38.

Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma.

Karydis I, Chan PY, Wheater M, Arriola E, Szlosarek PW, Ottensmeier CH.

Oncoimmunology. 2016 Feb 18;5(5):e1143997. doi: 10.1080/2162402X.2016.1143997. eCollection 2016 May.

39.

Gene expression analysis of TIL rich HPV-driven head and neck tumors reveals a distinct B-cell signature when compared to HPV independent tumors.

Wood O, Woo J, Seumois G, Savelyeva N, McCann KJ, Singh D, Jones T, Peel L, Breen MS, Ward M, Garrido Martin E, Sanchez-Elsner T, Thomas G, Vijayanand P, Woelk CH, King E, Ottensmeier C; SPARC Consortium.

Oncotarget. 2016 Aug 30;7(35):56781-56797. doi: 10.18632/oncotarget.10788.

40.

Validation of Immunomonitoring Methods for Application in Clinical Studies: The HLA-Peptide Multimer Staining Assay.

Chandran PA, Laske K, Cazaly A, Rusch E, Schmid-Horch B, Rammensee HG, Ottensmeier CH, Gouttefangeas C.

Cytometry B Clin Cytom. 2018 Mar;94(2):342-353. doi: 10.1002/cyto.b.21397. Epub 2016 Jul 22.

41.

Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC.

Arriola E, Wheater M, Galea I, Cross N, Maishman T, Hamid D, Stanton L, Cave J, Geldart T, Mulatero C, Potter V, Danson S, Woll PJ, Griffiths R, Nolan L, Ottensmeier C.

J Thorac Oncol. 2016 Sep;11(9):1511-21. doi: 10.1016/j.jtho.2016.05.028. Epub 2016 Jun 11.

42.

Upregulated Glucose Metabolism Correlates Inversely with CD8+ T-cell Infiltration and Survival in Squamous Cell Carcinoma.

Ottensmeier CH, Perry KL, Harden EL, Stasakova J, Jenei V, Fleming J, Wood O, Woo J, Woelk CH, Thomas GJ, Thirdborough SM.

Cancer Res. 2016 Jul 15;76(14):4136-48. doi: 10.1158/0008-5472.CAN-15-3121. Epub 2016 May 20.

43.

Mucosal-Associated Invariant T (MAIT) Cells Are Impaired in Th17 Associated Primary and Secondary Immunodeficiencies.

Gao Y, Rae W, Ramakrishnan KA, Barcenas-Morales G, Döffinger R, Eren E, Faust SN, Ottensmeier CH, Williams AP.

PLoS One. 2016 May 11;11(5):e0155059. doi: 10.1371/journal.pone.0155059. eCollection 2016.

44.

TG4010: a vaccine with a therapeutic role in cancer.

Arriola E, Ottensmeier C.

Immunotherapy. 2016 May;8(5):511-9. doi: 10.2217/imt-2016-0015. Review.

PMID:
27140406
45.
46.

Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes.

McCann KJ, Mander A, Cazaly A, Chudley L, Stasakova J, Thirdborough S, King A, Lloyd-Evans P, Buxton E, Edwards C, Halford S, Bateman A, O'Callaghan A, Clive S, Anthoney A, Jodrell DI, Weinschenk T, Simon P, Sahin U, Thomas GJ, Stevenson FK, Ottensmeier CH.

Clin Cancer Res. 2016 Oct 1;22(19):4827-4836. doi: 10.1158/1078-0432.CCR-15-2507. Epub 2016 Apr 18.

47.

Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma.

Noble F, Mellows T, McCormick Matthews LH, Bateman AC, Harris S, Underwood TJ, Byrne JP, Bailey IS, Sharland DM, Kelly JJ, Primrose JN, Sahota SS, Bateman AR, Thomas GJ, Ottensmeier CH.

Cancer Immunol Immunother. 2016 Jun;65(6):651-62. doi: 10.1007/s00262-016-1826-5. Epub 2016 Mar 28.

48.

Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study.

Mandruzzato S, Brandau S, Britten CM, Bronte V, Damuzzo V, Gouttefangeas C, Maurer D, Ottensmeier C, van der Burg SH, Welters MJ, Walter S.

Cancer Immunol Immunother. 2016 Feb;65(2):161-9. doi: 10.1007/s00262-015-1782-5. Epub 2016 Jan 4.

49.

TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.

Quoix E, Lena H, Losonczy G, Forget F, Chouaid C, Papai Z, Gervais R, Ottensmeier C, Szczesna A, Kazarnowicz A, Beck JT, Westeel V, Felip E, Debieuvre D, Madroszyk A, Adam J, Lacoste G, Tavernaro A, Bastien B, Halluard C, Palanché T, Limacher JM.

Lancet Oncol. 2016 Feb;17(2):212-223. doi: 10.1016/S1470-2045(15)00483-0. Epub 2015 Dec 23.

PMID:
26727163
50.

Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma.

Matthews LM, Noble F, Tod J, Jaynes E, Harris S, Primrose JN, Ottensmeier C, Thomas GJ, Underwood TJ.

Br J Cancer. 2015 Dec 22;113(12):1746. doi: 10.1038/bjc.2015.460. No abstract available.

Supplemental Content

Loading ...
Support Center